Epsilon variant - Epsilon (B.1.617.1) variant

Rosen, Gyorgy Snell, Amalio Telenti, Herbert W.

This mutation reduced the neutralizing activity of 14 out of 34 neutralizing antibodies specific to that domain, including clinical stage antibodies.

This study was supported by the National Institute of Allergy and Infectious Diseases at the National institutes of Health, Pew Biomedical Scholars Award, Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund, Fast Grants, Natural Sciences and Engineering Research Council of Canada, and Pasteur Institute.